XTX Topco Ltd Has $351,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

XTX Topco Ltd lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 70.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 8,919 shares of the company's stock after selling 21,103 shares during the period. XTX Topco Ltd's holdings in CRISPR Therapeutics were worth $351,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Sanctuary Advisors LLC raised its holdings in CRISPR Therapeutics by 17.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company's stock valued at $398,000 after acquiring an additional 1,258 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics during the third quarter valued at approximately $40,000. Franklin Resources Inc. raised its stake in shares of CRISPR Therapeutics by 12.7% in the third quarter. Franklin Resources Inc. now owns 7,097 shares of the company's stock valued at $339,000 after purchasing an additional 800 shares in the last quarter. Nordea Investment Management AB lifted its position in CRISPR Therapeutics by 4.4% in the fourth quarter. Nordea Investment Management AB now owns 125,400 shares of the company's stock worth $4,913,000 after purchasing an additional 5,300 shares during the period. Finally, Capital Market Strategies LLC acquired a new stake in CRISPR Therapeutics during the fourth quarter worth $461,000. Institutional investors own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CRSP. Evercore ISI raised shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and raised their price objective for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Citigroup lowered their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research note on Tuesday, February 18th. Barclays increased their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. TD Cowen upgraded CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price target on the stock in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, March 21st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $73.11.

CRISPR Therapeutics Trading Down 2.1 %

Shares of CRSP traded down $0.84 on Friday, reaching $38.27. 1,318,718 shares of the company's stock were exchanged, compared to its average volume of 1,642,353. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $67.88. The stock has a market capitalization of $3.31 billion, a P/E ratio of -8.76 and a beta of 1.85. The business has a 50 day moving average price of $40.02 and a two-hundred day moving average price of $43.51.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at approximately $350,516.46. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,381 shares of company stock worth $1,608,243. Corporate insiders own 4.10% of the company's stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.